AnaptysBio director granted options and RSUs

AnaptysBio, Inc. director John A. Orwin reported new equity awards on a Form 4.

Accepted by SEC EDGAR 01/08/2026 - 04:02 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

AnaptysBio, Inc. director John A. Orwin reported new equity awards on a Form 4. On January 6, 2026, he was granted a stock option covering 8,250 shares of common stock with an exercise price of $43.91 per share. This option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, as long as he continues providing service to the company on each vesting date.

On the same date, he also received 6,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration. These RSUs vest as to 100% of the total units on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service. Both the option and RSUs are reported as held directly.

Insider Trade Summary

Grant/Award: 14,250 shares

Grant/Award 2 txns

Insider Orwin John A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	8,250	$0.00	$0.00
Grant/Award	Restricted Stock Unit	6,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 8,250 contracts (Direct); Restricted Stock Unit — 6,000 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 8,250 contracts (Direct); Restricted Stock Unit, 0 to 6,000 contracts (Direct)

Footnotes (3)

1. F1. The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
2. F2. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
3. F3. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the reporting person in the AnaptysBio (ANAB) Form 4 filing?

The reporting person is John A. Orwin, who is listed as a director of AnaptysBio, Inc.

What stock options were granted to John A. Orwin in this ANAB Form 4?

He was granted a stock option for 8,250 shares of AnaptysBio common stock at an exercise price of $43.91 per share on January 6, 2026.

How do the stock options granted to the AnaptysBio director vest?

The stock option vests as to 1/12 of the total shares monthly, beginning on February 6, 2026, while he continues to provide service to AnaptysBio on each vesting date.

What restricted stock units (RSUs) did the AnaptysBio director receive?

John A. Orwin received 6,000 RSUs on January 6, 2026, each representing a contingent right to receive one share of AnaptysBio common stock for no consideration upon settlement.

When do the RSUs granted to the AnaptysBio director vest?

The 6,000 RSUs vest as to 100% of the total units on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service to the company.

Are the equity awards in this AnaptysBio Form 4 held directly or indirectly?

Both the 8,250 stock options and the 6,000 RSUs are reported as held with direct ownership (D) by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Orwin John A

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$43.91	01/06/2026		A		8,250		(1)	01/05/2036	Common Stock	8,250	$0	8,250	D
Restricted Stock Unit	(2)	01/06/2026		A		6,000		(3)	(3)	Common Stock	6,000	$0	6,000	D

Explanation of Responses:

1. The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

2. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

3. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Eric Loumeau, Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.